Member Info for JohnHenry

This is where Friel talks B ollocks most of the institutions from the placing have sold out

Looking at the price action i would say presentation presented further delays.

They are covered by one of the top US Biopharma Analysis. zero influence.

As no RNS then nothing new can be said unless they are planning an RNS tomorrow morning.

In which case ill read that.

Not at all i just dont see the point in these continuous rampy presentations. how many is that these last 6 months, since collaborating with red Chip, Bakers Dozen.

All it achieves is a spiky SP.

RNS when news is available.

Imho the Presentation is just another PR stunt, amongst the previous dozen. complete waste of time.

Just issue news through an RNS when available.

I certainly wont be tuning in.

Nothing from Budd, false promises once again ?

Leddachjack why would a main market listing increase the SP ?

The PA has for the first time since April trading below the 50 day moving average.

PA breaking down out of the consolidation pattern.

Im guessing the market is getting a little impatient for news.

Plus there are still Institutions bailing out from the placing

Aimho

out of the consolidation pattern so no breakout.

distributors in place to distribute zero tests. No Approvals.

should begin sometime today

Nas at 91p so pretty much down to UK level.

Camkite i take it youve never heard of the 3 day rule after a shock negative RNS.

3 day rule after shock news, low sometime tomorrow. imho

LB28 how do you know the size of the overhang ? Could be an iceberg.

Looks likely, selling relentless.

Absolutely Rachel

SO in MAY when SNG were conducting initial trials the company had an EV of £105M Now with a hugely successful Phase 2 trial and fully funded Phase 3 trials about to start the company as an EV value of £90M